News Archive

Rockville, Md. (August 5, 2024) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, announced today that Damien Bates, MD, PhD, FRACS, MBA joined the company as Chief Medical Officer.

Cellphire Therapeutics is excited to announce the appointment of Dr. Damien Bates as Chief Medical Officer. Dr. Bates brings a wealth of experience in clinical development and strategic leadership to the role. In his new position, Dr. Bates will spearhead both strategic initiatives in clinical development and daily clinical operations, driving forward the company’s vision of saving lives with transformative stabilized cellular therapeutics. His track record of success in the clinical development and regulatory approval of multiple allogeneic cell therapies, key opinion leader engagement and operational excellence will be instrumental in advancing Cellphire’s innovative pipeline and ensuring the successful execution of its clinical programs. We are thrilled to welcome Dr. Bates to the team and look forward to the impact of his expertise on our continued growth and success.

The 7th Annual Investment Conference, scheduled for September 19th during the BioHealth Capital Region Week at US Pharmacopeia in Rockville, MD, offers a unique platform for companies and investors. Attendees will have the opportunity to create detailed profiles and schedule face-to-face meetings throughout the day to discuss potential collaborations and funding. Simultaneously, the auditorium will feature a series of quick pitches, providing selected companies and some investors with 7 minutes each to introduce themselves and present their ideas in front of an audience of peers and potential partners.

Why Investors Should Attend

For investors, this conference is an indispensable opportunity to access a curated selection of startups with groundbreaking ideas poised for investment. It offers a chance to engage directly with founders, understand their business models, and evaluate their potential in person. Investors can gain early insights into emerging technologies and trends, potentially leading to profitable investment opportunities and partnerships. Register Now.

Why Companies Should Attend

For companies, the Investment Conference is a vital avenue to meet face-to-face with leading investors actively looking to fund innovative projects and businesses. It provides a platform not only for potential funding but also for valuable feedback and advice on scaling their operations. The quick-pitch sessions offer companies a chance to capture attention, showcase their innovations, and articulate their vision to a room full of potential backers. Register Now.

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced the introduction of a new NARCANDirect™ distribution center in Nevada to further demonstrate its commitment to broadening access to NARCAN^® Nasal Spray nationwide. This new facility allows Emergent to further meet the increased demand for naloxone by now having coast-to-coast distribution mechanisms in place to continue to provide faster, more efficient delivery to public interest customers, as well as other purchasing entities.

NARCANDirect™ is an online portal that enables qualified direct purchasers, such as emergency medical services, law enforcement, fire departments, government agencies, schools/universities, and community-based naloxone distribution programs, to purchase and ship NARCAN^® Nasal Spray directly.

GSK and Flagship Pioneering have entered into a partnership worth up to $7bn to discover and develop novel medicines and vaccines for a range of conditions.

Bringing together GSK’s expertise in disease and development capability via Flagship’s ecosystem of bioplatform companies, the collaboration aims to develop a portfolio of up to ten future medicines and vaccines, beginning in respiratory and immunology, which will each be subject to an exclusive option by GSK for further clinical development.

ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 31, 2024 /PRNewswire/ — Sirnaomics Ltd. (the “Company“, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics“), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced a partnership with Gore Range Capital LLC (“Gore Range Capital“) (Dallas, TX, USA) for establishment of a joint venture, Sagesse Bio, Inc., to advance its novel RNAi therapeutic products into aesthetic medicine.

GAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a leader in AI-driven drug discovery, announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). Building on the progress detailed in our May 16, 2024 release, our research has now pinpointed specific molecular pathways associated with bipolar disorder (BD), enabling the identification of new candidate drug targets.

GAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) — Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first patient has been dosed with GIM-531 in a first-in-human, phase 1 clinical trial for the treatment of advanced cancer patients. GIM-531 development focuses on indications that are currently not addressed with existing or available immunotherapies including anti-PD-1 antibodies. It is an oral therapy that is a first-in-class selective T regulatory cell inhibitor.

GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL^® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purchase price of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon achievement of a milestone related to the sourcing of a certain component of RSDL^®. The transaction has signed and closed simultaneously. 

In addition, SERB will acquire and maintain operations of Emergent’s leased manufacturing facility in Hattiesburg, Mississippi, and several site-based employees who support RSDL^® will join SERB. SERB will also acquire the RSDL^® product inventory as part of the transaction and will assume certain related contracts. Emergent’s Winnipeg facility will continue to manufacture and supply bulk lotion to SERB under a long-term supply agreement between the two companies.

ROCKVILLE, Md., July 30, 2024—The Montgomery County Council voted today to approve the Planning Board Draft of the Great Seneca Plan: Connecting Life and Science with revisions. The plan covers 4,330 acres located in the heart of the I-270 Corridor between the cities of Gaithersburg and Rockville and the town of Washington Grove. The Plan makes recommendations to strengthen the economic competitiveness of the Life Sciences Center, guide future developments, and transform public spaces and amenities in the area to provide valuable links and social spaces. 

“The Great Seneca Science Corridor is one of Montgomery County’s most important strategic areas, as the heart of our globally recognized biohealth industry with world-class research, education, and health care facilities,” said Council President Andrew Friedson who also chairs the Planning, Housing and Parks (PHP) Committee. “This plan builds on that strength by creating a more sustainable and vibrant community with greater connectivity to improve quality of life and economic competitiveness.”